Applied DNA Sciences, Inc.

335 articles with Applied DNA Sciences, Inc.

• Applied DNA Reports Second Quarter Fiscal 2022 Financial Results

  5/12/2022

  Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, announced consolidated financial results for the second quarter of fiscal 2022, ended March 31, 2022.

• Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022

  5/9/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022.

• Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT

  3/23/2022

  During the virtual conference, investors will hear from executives from a wide range of sectors, including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITs, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/Media/Telecom.

• Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

  3/14/2022

  Applied DNA Sciences, Inc. today announced that the two companies have executed a non-binding letter of intent (“LOI”) that outlines the terms of a collaborative research agreement (the “Definitive Agreement”) to investigate the feasibility of utilizing the Company’s LinearDNATM platform.

• Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference

  3/10/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that Chief Executive Officer Dr. James A. Hayward will host a virtual fireside chat with the Company's covering analyst, Managing Director and Senior Research Analyst Jonathan Aschoff, on Monday, March 14, 2022, at the 34th Annual ROTH Investor Conference.

• Applied DNA Announces Closing of $4.2 Million Registered Direct Offering

  2/24/2022

  Applied DNA Sciences, Inc. announced the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock at a price of $2.80 per share for gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

• Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering

  2/22/2022

  Applied DNA Sciences, Inc. announced that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock at a price of $2.80 per share, in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other estimated offering expenses.

• Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

  2/17/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), and its program development partner, EvviVax, S.R.L. ("Evvivax"), today announced the publication of a manuscript detailing a preclinical study (the “study”) showing that LinearDNA™ vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models.

• Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues

  2/10/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021.

• Applied DNA Schedules Fiscal 2022 First Quarter Financial Results Conference Call and Webcast for Thursday, February 10, 2022

  2/3/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022.

• Applied DNA to Deploy Linea™ 1.0 COVID-19 Assay for Rapid Detection of New Omicron Subvariant BA.2

  1/28/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), intends to deploy its Linea™ 1.0 COVID-19 Assay (the “Linea 1.0 Assay” or the “Assay”), part of ADCL’s Linea COVID-19 diagnostics and testing portfolio, for the rapid detection of samples containing a mutation profile that is indicative of the BA.2 subvariant (BA.2) of Omicron in COVID-19-positive samples.

• Applied DNA Submits Request for Emergency Use Authorization to FDA for Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit

  1/21/2022

  Applied DNA Sciences, Inc. announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 COVID-19 Assay and Linea™ Unsupervised At-Home Sample Collection Kit.

• Applied DNA Announces Continued Momentum in COVID-19 Testing Demand

  1/18/2022

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, has seen COVID-19 testing levels increase greater than 90% for the quarter ended December 31, 2021, compared to the fiscal quarter ended September 30, 2021.

• Applied DNA Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

  1/4/2022

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State Department of Health (NYSDOH) for its Linea™ 2.0 Assay (the “Linea 2.0 Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH.

• Applied DNA and Stratum Reservoir (Isotech) Sign Memorandum of Understanding to Leverage Isotopic Analysis for Enhanced DNA-Based Cotton Authenticity and Provenance

  12/15/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), and Stratum Reservoir (Isotech), LLC (“Isotech”), today announced that they have entered into a Memorandum of Understanding (MoU).

• Applied DNA Reports Fourth Quarter and Full Fiscal Year 2021 Financial Results, Continuing Momentum in Diagnostic Testing

  12/9/2021

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021.

• Applied DNA Advances Cotton Genomics-based Methodology for Determination of Authenticity and Provenance

  12/6/2021

  Applied DNA Sciences, Inc. announced today a development in its cotton genomics program (the “Program”) that the Company believes can bring forensic proof of cotton authenticity and provenance specifically related to regional cotton varietals to give brands and relevant regulatory authorities access to fiber origin data regardless of location of manufacture.

• Applied DNA Schedules Fourth Quarter and Full Fiscal Year 2021 Financial Results Conference Call and Webcast for Thursday, December 9, 2021

  12/3/2021

  Applied DNA Sciences, Inc. today announced that it will report its fourth quarter and full fiscal year 2021 financial results after market close on Thursday, December 9, 2021.

• Applied DNA Announces Strategy to Address Omicron SARS-CoV-2 Variant, Introduces Linea™ 2.0 COVID-19 Assay Kit

  11/29/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, announced its COVID-19 diagnostic strategy in response to the emergence of Omicron, a newly identified SARS-CoV-2 variant of concern.

• Applied DNA Subsidiary LineaRx Receives Repeat Orders for LinearDNA, Adds Federally Funded Cancer Research Laboratory as CRO Customer

  11/15/2021

  Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction -based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research.